Study to Investigate the Natriuretic Effects, Safety, Tolerability and Pharmacokinetics of BAY94-8862

• Status: Completed
• Trial end date: 2011-05-01
• Target enrollment: 0
• Participant gender: Male

Summary

Pharmacodynamics, pharmacokinetics, safety, and tolerability will be investigated in this single dose study. In 5 treatment groups, different dosages of BAY94-8862 will be given in healthy male subjects.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Bayer
• Treatments: Eplerenone; Fludrocortisone; Pharmaceutical Solutions; Spironolactone

Criteria

Inclusion Criteria:

• Healthy male white subjects

• 18 to 46 years of age

• Body mass index (BMI): 18 - 29.9 kg/m²

Exclusion Criteria:

• Clinically relevant findings in medical history or in the physical examination

• Systolic blood pressure below 100 or above 140 mmHg

• Diastolic blood pressure below 50 or above 90 mmHg

• Heart rate below 45 or above 95 beats / min